Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2003

View Archived Issues

Heterocyclic antiobesity agents in early development at Bayer

New quinolone-based antibacterial agents prepared and tested at Sato

Kyoto Pharmaceutical and Sankyo present novel carbapenem antibiotics

Boehringer Ingelheim patent covers cathepsin inhibitors for autoimmune diseases and other uses

Takeda scientists identify novel MCH receptor antagonists

New 5-HT1B/5-HT1D antagonists and their use claimed by AstraZeneca

Five related series of COX-2 inhibitors reported by Pfizer in recent patents

Use of donepezil in vascular dementia and Alzheimer's disease discussed at AGS meeting

Additional benefits reported for eplerenone combined with other drugs in hypertension

Recent clinical findings for olmesartan medoxomil reported at ASH meeting

LY-293111 improves the antitumor efficacy of gemcitabine in a murine pancreatic cancer model

Seretide approved in E.U.

Peninsula and Shionogi reach doripenem licensing agreement

Orphan drug status sought for CTCE-9908 in Europe

Nippon Shinyaku acquires Japanese rights to acamprosate

Mitsubishi files for European approval of argatroban, establishes German subsidiary

Oxytrol submission accepted for review in Canada

Japanese sNDA submitted for Cleactor for acute pulmonary embolism

NIH grant supports development of E-Matrix for diabetic foot ulcers

Endocyte begins phase I trial of FolateImmune for cancer

Restructuring at Northwest Biotherapeutics

BioTie Therapies updates progress

Inhibitor of calcium-activated chloride channel evaluated in mouse model of mucus hypersecretion

Neuroprotective antioxidant effective in rodent models of Parkinson's disease

Potential of potent and selective adenosine A1 antagonist in the oral treatment of asthma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026